Eight-year experience of malignant lymphoma - Survival and prognostic factors

Yonsei Medical Journal

Volumn 38, Issue 5, 1997, Pages 270-284

  Hahn, Jee Sook ^a   Lee, Seok ^a   Chong, So Young ^a   Min, Yoo Hong ^a   Ko, Yun Woong ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Malignant lymphoma; Prognostic factor; Survival

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; KOREA; LYMPHOMA; MAJOR CLINICAL STUDY; PROGNOSIS; REMISSION; RISK FACTOR; SURVIVAL; SURVIVAL RATE;

EID: 9844228516     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.1997.38.5.270     Document Type: Article

References (29)

1. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328: 1023-1030, 1993
2. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the committee of Hodgkin's disease staging classification. Cancer Res 31: 1860-1861, 1971
3. Coiffier B, Bastion Y, Berger F, Felman P, Bryon PA: Prognostic factors in follicular lymphomas. Semin Oncol 20: 89-95, 1993
4. DeVita VT Jr, Hellman S, Jaffe ES: Hodgkin's disease. In DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology, 4th ed. Philadelphia, J.B. Lippincott, 1993, 1819-1858
5. DeVita VT Jr, Hubbard SM: Hodgkin's disease. N Engl J Med 328: 560-565, 1993
6. Freeman C, Berg JW, Cutler SJ: Occurrence and prognosis of extranodal lymphomas. Cancer 29: 252-260, 1972
7. Hahn JS, Ko YW, Min YH, Kim NK, Kim DJ, Kim MC, Kim BS, Kim SY, Kim SH, Kim JS, Park BC, Park SC, Park JH, Park HS, Suh CI, Sun DJ, Song HS, Shim YH, Oh DY, Lee KS, Lee KB, Lee S, Lee SN, Lee ST, Lee JH, Chun CH, Jung HC, Cho KS, Cho KJ, Jin CJ, Choi IY, Choi JH, Hyun MS: Statistical analysis of malignant lymphoma in Korea. Kor J Hematol 30: 197-214, 1995
8. Hutchison RE, Berard CW, Shuster JJ, Link MP, Pick TE, Murphy SB: B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: A pediatric oncology group study. J Clin Oncol 13: 2023-2032, 1995
9. Kadin ME, Berard CW, Nanba K, Wakasa H: Lymphoproliferative diseases in Japan and Western countries. Hum Pathol 14: 745-770, 1983
10. Kim CW, Kim IS, Ko YH, Cho HJ, Yang WI, Kwon GY, Lee DG, Moon HB, Suh CH, Juhng SW, Lee JD, Kim SH: Clinicopathologic and immunophenotypic study of non-Hodgkin's lymphoma in Korea. J Korean Med Sci 7: 193-198, 1992a
11. Kim H, Zelamna RJ, Fox MA, Bennett JM, Berard CW, Butler JJ, Byrne GE, Dorfman RF, Hartsock RJ, Lukes RJ, Mann RB, Neiman RS, Rebuck JW, Sheehan WW, Variakoojis D, Wilson JF, Rappaport H: Pathology panel for lymphoma clinical studies: A comprehensive analysis of cases accumulated since its inception. J Natl Cancer Inst 68: 43-67, 1982
12. Kim HT, Im YH, Suh CI, Park YS, Kang WK, Heo DS, Bang YJ, Park SY, Kim BK, Kim NK: Malignant lymphomas in Korea. J Korean Cancer 24: 92-101, 1992b
13. Levin PH, Hoover R: The emerging epidemic of non-Hodgkin's lymphoma: Current knowledge regarding etiological factors. Cancer Epidemiol Biomark Prev 1: 515-517, 1992
14. Longo DL, Duffey PL, DeVita VT Jr, Wiernik PH, Hubbard SM, Phares JC, Bastian AW, Jaffe ES, Young RC: Treatment of advanced-stage Hodgkin's disease: Alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol 9: 1409-1420, 1991
15. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, DeVita VT Jr: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4: 1295-1306, 1986
16. Lukes RJ, Butler JJ: The pathology and nomenclature of Hodgkin's disease. Cancer Res 26: 1063-1081, 1966
17. Lukes RJ, Parker JW, Taylor CR, Tindle BH, Cramer AD, Lincoln TL: Immunologic approaches to non-Hodgkin's lymphoma and related disorders. Analysis of the results of multiparameter studies of 425 cases. Semin Hematol 5: 322-351, 1978
18. Muller NE: Hodgkin's disease. In Schnottenfeld D, Fraumeni J, eds. Cancer epidemiology and prevention, 2nd ed. New York, Oxford University Press, 1992, 1-35
19. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49: 2112-2135, 1982
20. Newell GR, Cabanillas FG, Hagemeister FJ, Bufler JJ: Incidence of lymphoma in the US classified by the Working Formulation. Cancer 59: 857-862, 1987
21. Shih LY, Liang DC: Non-Hodgkin's lymphomas in Asia. Hematol Oncol Clin North Am 5: 983-1001, 1991
22. Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 83: 1165-1173, 1994
23. Shipp MA, Harrington DP: International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994, 1993
24. Shivdasani RA, Hess JL, Skarin AT, Pinkus GS: Intermediate lymphocytic lymphoma: Clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma. J Clin Oncol 11: 802-811, 1993
25. Su IJ, Shin LY, Kadin ME, Dun P, Hsu SM: Pathologic and immunologic characterization of malignant lymphoma in Taiwan. Am J Clin Pathol 84: 715-723, 1985
26. Suchi T, Tajima K: Peripheral T-cell malignancy as a problem in lymphoma classification. Jpn J Clin Oncol 9: 443-450, 1979
27. Talvalkar GV, Sampat MB, Gangadharan P: Hodgkin's disease in Western India. Review of 1082 cases. Cancer 50: 353-362, 1982
28. Vose JM, Bierman PJ, Weisenburger DD, Armitage JO: The therapy of non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 5: 845-852, 1991
29. Yi PI, Coleman MC, Saltz L, Norton L, Topilow AA, Adler K, Bernhardt B: Chemotherapy for large cell lymphoma: A status update. Semin Oncol 17: 60-71, 1990